ARGOS VISION INC.

Biotech

A multi-target small molecule drug (CM-20) that dual-targets mitochondria and GPCRs to protect photoreceptors and RPE cells in retinal degeneration.

Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Dual Targeting Mitochondria and GPCR in Retinal Protection$255,710
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3007EARNANO, LLC——
3008SPEKCITON BIOSCIENCES LLC——
3009MONTANA MOLECULAR, LLC——
3010ARGOS VISION INC.——
3011BACSTITCH DNA INC.——
3012Aincobio LLC——
3013VORTEX BIOTECHNOLOGY CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Contact Lenses Comprising Hydrogel Coatings And Method Of Forming Contact Lenses With Hydrogel Coatingsapplication
  • Contact Lenses Comprising Hydrogel Coatings And Method Of Forming Contact Lenses With Hydrogel Coatingsapplication
  • Methods Of Forming Contact Lenses To Reduce The Transmittance Of Lightapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.